Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study)
Dolutegravir plus darunavir/cobicistat is a durable combination in heavily treatment-experienced PWH. Those who were viraemic at the time of switch were more likely to discontinue, although most reasons for TD were other than virological failure.
Authors
- Daniela Valenti (ORCID: https://orcid.org/0000-0001-7638-8724)
- Maurizio Zazzi (ORCID: https://orcid.org/0000-0002-0344-6281)
- Davide Moschese (ORCID: https://orcid.org/0000-0001-5901-6742)
- Maria Mazzitelli (ORCID: https://orcid.org/0000-0003-0263-0703)
- Roberto Gulminetti (ORCID: https://orcid.org/0000-0002-8456-3550)
- Andrea Giacomelli (ORCID: https://orcid.org/0000-0003-3685-4289)
- Laura Comi (ORCID: https://orcid.org/0000-0002-0848-2847)
- Teresa Bini
- Massimiliano Fabbiani (ORCID: https://orcid.org/0000-0002-1343-812X)
- Anna Maria Cattelan (ORCID: https://orcid.org/0000-0003-2869-2945)
- Andrea Francavilla (ORCID: https://orcid.org/0000-0002-1980-0871)
- Maria Vittoria Cossu (ORCID: https://orcid.org/0000-0002-6984-3028)
- Layla Pagnucco
- Paolo Bonfanti (ORCID: https://orcid.org/0000-0001-7289-8823)
- Giuseppe Lapadula (ORCID: https://orcid.org/0000-0002-9976-8102)
- Luca Mezzadri (ORCID: https://orcid.org/0009-0000-5652-3204)
- Diego Ripamonti (ORCID: https://orcid.org/0000-0001-6702-6668)
Institutions
- University of Siena (IT)
- AOL (United States) (US)
- University of Padua (IT)
- University of Milan (IT)
- University of Pavia (IT)
- Ospedale Papa Giovanni XXIII (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- ASST Fatebenefratelli Sacco (IT)
- Ospedale generale di zona San Camillo Treviso (IT)
- Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1093/jac/dkaf119
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Gilead Sciences
- ViiV Healthcare
- Cilag